Sodium-glucose cotransporter 2 inhibitors and the treatment of acute coronary syndrome: Does the use make sense?

Abstract

Sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) represent a therapeutic modality option for type 2 diabetes mellitus. This group of drugs includes dapagliflozin, empagliflozin, canagliflozin, ertugliflozin and sotagliflozin. Given their proven benefit in the scope of heart failure through clinical studies, they have also gained their place in patients with reduced, moderately reduced, or preserved systolic function of the left ventricle. Due to the effect on both the systolic and diastolic function of the left ventricle, and the neurohumoral activity itself, their range of use has been expanded in patients without a history of diabetes mellitus, and empagliflozin in a dose of 10 mg, as well as dapagliflozin in a dose of 10 mg, have been implemented in patients without diabetes mellitus. New directions for the expansion of the use of SGLT2 inhibitors have pointed towards their applicability in acute heart failure (sotagliflozin) and type 1 diabetes (sotagliflozin). Recently, clinical studies concerning the use of empagliflozin and dapagliflozin in acute coronary syndrome (ACS), appeared. The aim of this paper was to highlight the possible benefit of including SGLT2 inhibitors in patients with ACS.